APO Research
Talk to an analyst

APO RESEARCH · REPORT

Febrile Neutropenia

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Febrile Neutropenia Market Outlook and Growth Opportunities 2026

31 December 2025191 pages

Choose your research edition.

Industry ResearchFebrile Neutropenia Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Febrile Neutropenia Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Febrile Neutropenia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Febrile Neutropenia Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Febrile Neutropenia Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Febrile Neutropenia market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Febrile Neutropenia is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Febrile Neutropenia market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Febrile Neutropenia market include BeyondSpring Inc., Eli Lilly and Company, Taiho Pharmaceutical Co., Ltd., Amgen Inc., Xenetic Biosciences, Inc. (XBIO), USV Private Limited, Richter Gedeon Nyrt., Hospira, Inc. and Aequus BioPharma, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Febrile Neutropenia market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Febrile Neutropenia and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Febrile Neutropenia revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Febrile Neutropenia market.

Febrile Neutropenia Segment by Company

BeyondSpring Inc.

Eli Lilly and Company

Taiho Pharmaceutical Co., Ltd.

Amgen Inc.

Xenetic Biosciences, Inc. (XBIO)

USV Private Limited

Richter Gedeon Nyrt.

Hospira, Inc.

Aequus BioPharma, Inc.

Febrile Neutropenia Segment by Type

Filgrastim Biosimilars

Pegfilgrastim

Pegfilgrastim Biosimilars

Vancomycin Hydrochloride

Others

Febrile Neutropenia Segment by Application

Hospitals

Clinics

Others

Febrile Neutropenia Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Febrile Neutropenia status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Febrile Neutropenia key companies, revenue, market share, and recent developments.

3. To split the Febrile Neutropenia breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Febrile Neutropenia market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Febrile Neutropenia significant trends, drivers, influence factors in global and regions.

6. To analyze Febrile Neutropenia competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Febrile Neutropenia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Febrile Neutropenia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Febrile Neutropenia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Febrile Neutropenia industry.

Chapter 3: Detailed analysis of Febrile Neutropenia company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Febrile Neutropenia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Febrile Neutropenia in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Febrile Neutropenia Industry Trends Table 2. Febrile Neutropenia Industry Drivers Table 3. Febrile Neutropenia Industry Opportunities and Challenges Table 4. Febrile Neutropenia Industry Restraints Table 5. Global Febrile Neutropenia Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Febrile Neutropenia Revenue Share by Company (2021-2026) Table 7. Global Febrile Neutropenia Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Febrile Neutropenia Key Company Manufacturing Base & Headquarters Table 9. Global Febrile Neutropenia Company, Product Type & Application Table 10. Global Febrile Neutropenia Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Febrile Neutropenia by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Filgrastim Biosimilars Table 15. Significant Companies of Pegfilgrastim Table 16. Significant Companies of Pegfilgrastim Biosimilars Table 17. Significant Companies of Vancomycin Hydrochloride Table 18. Significant Companies of Others Table 19. Global Febrile Neutropenia Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Febrile Neutropenia Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Febrile Neutropenia Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Febrile Neutropenia Sales Value Share by Type (2021-2026) Table 23. Global Febrile Neutropenia Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Clinics Table 26. Significant Companies of Others Table 27. Global Febrile Neutropenia Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Febrile Neutropenia Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Febrile Neutropenia Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Febrile Neutropenia Sales Value Share by Application (2021-2026) Table 31. Global Febrile Neutropenia Sales Value Share by Application (2027-2032) Table 32. Global Febrile Neutropenia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Febrile Neutropenia Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Febrile Neutropenia Sales Value Share by Region (2021-2026) Table 35. Global Febrile Neutropenia Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Febrile Neutropenia Sales Value Share by Region (2027-2032) Table 37. Global Febrile Neutropenia Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Febrile Neutropenia Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Febrile Neutropenia Sales Value Market Share by Country (2021-2026) Table 40. Global Febrile Neutropenia Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Febrile Neutropenia Sales Value Market Share by Country (2027-2032) Table 42. BeyondSpring Inc. Company Information Table 43. BeyondSpring Inc. Business Overview Table 44. BeyondSpring Inc. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. BeyondSpring Inc. Febrile Neutropenia Product Portfolio Table 46. BeyondSpring Inc. Recent Development Table 47. Eli Lilly and Company Company Information Table 48. Eli Lilly and Company Business Overview Table 49. Eli Lilly and Company Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Eli Lilly and Company Febrile Neutropenia Product Portfolio Table 51. Eli Lilly and Company Recent Development Table 52. Taiho Pharmaceutical Co., Ltd. Company Information Table 53. Taiho Pharmaceutical Co., Ltd. Business Overview Table 54. Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product Portfolio Table 56. Taiho Pharmaceutical Co., Ltd. Recent Development Table 57. Amgen Inc. Company Information Table 58. Amgen Inc. Business Overview Table 59. Amgen Inc. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Amgen Inc. Febrile Neutropenia Product Portfolio Table 61. Amgen Inc. Recent Development Table 62. Xenetic Biosciences, Inc. (XBIO) Company Information Table 63. Xenetic Biosciences, Inc. (XBIO) Business Overview Table 64. Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product Portfolio Table 66. Xenetic Biosciences, Inc. (XBIO) Recent Development Table 67. USV Private Limited Company Information Table 68. USV Private Limited Business Overview Table 69. USV Private Limited Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. USV Private Limited Febrile Neutropenia Product Portfolio Table 71. USV Private Limited Recent Development Table 72. Richter Gedeon Nyrt. Company Information Table 73. Richter Gedeon Nyrt. Business Overview Table 74. Richter Gedeon Nyrt. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Richter Gedeon Nyrt. Febrile Neutropenia Product Portfolio Table 76. Richter Gedeon Nyrt. Recent Development Table 77. Hospira, Inc. Company Information Table 78. Hospira, Inc. Business Overview Table 79. Hospira, Inc. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Hospira, Inc. Febrile Neutropenia Product Portfolio Table 81. Hospira, Inc. Recent Development Table 82. Aequus BioPharma, Inc. Company Information Table 83. Aequus BioPharma, Inc. Business Overview Table 84. Aequus BioPharma, Inc. Febrile Neutropenia Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Aequus BioPharma, Inc. Febrile Neutropenia Product Portfolio Table 86. Aequus BioPharma, Inc. Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Febrile Neutropenia Product Image Figure 2. Global Febrile Neutropenia Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Febrile Neutropenia Market Size (2021-2032) & (US$ Million) Figure 4. Global Febrile Neutropenia Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Filgrastim Biosimilars Image Figure 8. Pegfilgrastim Image Figure 9. Pegfilgrastim Biosimilars Image Figure 10. Vancomycin Hydrochloride Image Figure 11. Others Image Figure 12. Global Febrile Neutropenia Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Febrile Neutropenia Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Febrile Neutropenia Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Clinics Image Figure 17. Others Image Figure 18. Global Febrile Neutropenia Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Febrile Neutropenia Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Febrile Neutropenia Sales Value Share by Application (2021-2032) Figure 21. Global Febrile Neutropenia Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Febrile Neutropenia Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Febrile Neutropenia Sales Value (2021-2032) & (US$ Million) Figure 24. North America Febrile Neutropenia Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Febrile Neutropenia Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Febrile Neutropenia Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Febrile Neutropenia Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Febrile Neutropenia Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Febrile Neutropenia Sales Value (2021-2032) & (US$ Million) Figure 30. South America Febrile Neutropenia Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Febrile Neutropenia Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Febrile Neutropenia Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Febrile Neutropenia Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Filgrastim Biosimilars
  • Pegfilgrastim
  • Pegfilgrastim Biosimilars
  • Vancomycin Hydrochloride
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • BeyondSpring Inc.
  • Eli Lilly and Company
  • Taiho Pharmaceutical Co., Ltd.
  • Amgen Inc.
  • Xenetic Biosciences, Inc. (XBIO)
  • USV Private Limited
  • Richter Gedeon Nyrt.
  • Hospira, Inc.
  • Aequus BioPharma, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Febrile Neutropenia Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Febrile Neutropenia Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Febrile Neutropenia Market Dynamics
  1. 2.1 Febrile Neutropenia Industry Trends
  2. 2.2 Febrile Neutropenia Industry Drivers
  3. 2.3 Febrile Neutropenia Industry Opportunities and Challenges
  4. 2.4 Febrile Neutropenia Industry Restraints
3 Febrile Neutropenia Market by Company
  1. 3.1 Global Febrile Neutropenia Company Revenue Ranking in 2025
  2. 3.2 Global Febrile Neutropenia Revenue by Company (2021-2026)
  3. 3.3 Global Febrile Neutropenia Company Ranking (2024-2026)
  4. 3.4 Global Febrile Neutropenia Company Manufacturing Base and Headquarters
  5. 3.5 Global Febrile Neutropenia Company Product Type and Application
  6. 3.6 Global Febrile Neutropenia Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Febrile Neutropenia Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Febrile Neutropenia Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Febrile Neutropenia Market by Type
  1. 4.1 Febrile Neutropenia Type Introduction
  2. 4.1.1 Filgrastim Biosimilars
  3. 4.1.2 Pegfilgrastim
  4. 4.1.3 Pegfilgrastim Biosimilars
  5. 4.1.4 Vancomycin Hydrochloride
  6. 4.1.5 Others
  7. 4.2 Global Febrile Neutropenia Sales Value by Type
  8. 4.2.1 Global Febrile Neutropenia Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Febrile Neutropenia Sales Value by Type (2021-2032)
  10. 4.2.3 Global Febrile Neutropenia Sales Value Share by Type (2021-2032)
5 Febrile Neutropenia Market by Application
  1. 5.1 Febrile Neutropenia Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Febrile Neutropenia Sales Value by Application
  6. 5.2.1 Global Febrile Neutropenia Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Febrile Neutropenia Sales Value by Application (2021-2032)
  8. 5.2.3 Global Febrile Neutropenia Sales Value Share by Application (2021-2032)
6 Febrile Neutropenia Regional Value Analysis
  1. 6.1 Global Febrile Neutropenia Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Febrile Neutropenia Sales Value by Region (2021-2032)
  3. 6.2.1 Global Febrile Neutropenia Sales Value by Region: 2021-2026
  4. 6.2.2 Global Febrile Neutropenia Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Febrile Neutropenia Sales Value (2021-2032)
  7. 6.3.2 North America Febrile Neutropenia Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Febrile Neutropenia Sales Value (2021-2032)
  10. 6.4.2 Europe Febrile Neutropenia Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Febrile Neutropenia Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Febrile Neutropenia Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Febrile Neutropenia Sales Value (2021-2032)
  16. 6.6.2 South America Febrile Neutropenia Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Febrile Neutropenia Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Febrile Neutropenia Sales Value Share by Country, 2025 VS 2032
7 Febrile Neutropenia Country-level Value Analysis
  1. 7.1 Global Febrile Neutropenia Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Febrile Neutropenia Sales Value by Country (2021-2032)
  3. 7.2.1 Global Febrile Neutropenia Sales Value by Country (2021-2026)
  4. 7.2.2 Global Febrile Neutropenia Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Febrile Neutropenia Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Febrile Neutropenia Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Febrile Neutropenia Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BeyondSpring Inc.
  2. 8.1.1 BeyondSpring Inc. Company Information
  3. 8.1.2 BeyondSpring Inc. Business Overview
  4. 8.1.3 BeyondSpring Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BeyondSpring Inc. Febrile Neutropenia Product Portfolio
  6. 8.1.5 BeyondSpring Inc. Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Febrile Neutropenia Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Taiho Pharmaceutical Co., Ltd.
  14. 8.3.1 Taiho Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Taiho Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Taiho Pharmaceutical Co., Ltd. Febrile Neutropenia Product Portfolio
  18. 8.3.5 Taiho Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Amgen Inc.
  20. 8.4.1 Amgen Inc. Company Information
  21. 8.4.2 Amgen Inc. Business Overview
  22. 8.4.3 Amgen Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Amgen Inc. Febrile Neutropenia Product Portfolio
  24. 8.4.5 Amgen Inc. Recent Developments
  25. 8.5 Xenetic Biosciences, Inc. (XBIO)
  26. 8.5.1 Xenetic Biosciences, Inc. (XBIO) Company Information
  27. 8.5.2 Xenetic Biosciences, Inc. (XBIO) Business Overview
  28. 8.5.3 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Xenetic Biosciences, Inc. (XBIO) Febrile Neutropenia Product Portfolio
  30. 8.5.5 Xenetic Biosciences, Inc. (XBIO) Recent Developments
  31. 8.6 USV Private Limited
  32. 8.6.1 USV Private Limited Company Information
  33. 8.6.2 USV Private Limited Business Overview
  34. 8.6.3 USV Private Limited Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  35. 8.6.4 USV Private Limited Febrile Neutropenia Product Portfolio
  36. 8.6.5 USV Private Limited Recent Developments
  37. 8.7 Richter Gedeon Nyrt.
  38. 8.7.1 Richter Gedeon Nyrt. Company Information
  39. 8.7.2 Richter Gedeon Nyrt. Business Overview
  40. 8.7.3 Richter Gedeon Nyrt. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Richter Gedeon Nyrt. Febrile Neutropenia Product Portfolio
  42. 8.7.5 Richter Gedeon Nyrt. Recent Developments
  43. 8.8 Hospira, Inc.
  44. 8.8.1 Hospira, Inc. Company Information
  45. 8.8.2 Hospira, Inc. Business Overview
  46. 8.8.3 Hospira, Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hospira, Inc. Febrile Neutropenia Product Portfolio
  48. 8.8.5 Hospira, Inc. Recent Developments
  49. 8.9 Aequus BioPharma, Inc.
  50. 8.9.1 Aequus BioPharma, Inc. Company Information
  51. 8.9.2 Aequus BioPharma, Inc. Business Overview
  52. 8.9.3 Aequus BioPharma, Inc. Febrile Neutropenia Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Aequus BioPharma, Inc. Febrile Neutropenia Product Portfolio
  54. 8.9.5 Aequus BioPharma, Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst